Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Abstract: Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Abstract: A process for producing cation crystals of growth hormone or growth hormone derivatives, as well as growth hormone and growth hormone derivatives. The process of producing the growth hormone crystals includes the steps of (a) adding cations of inorganic or organic nature and an organic solvent or a mixture of inorganic solvents at a pH between 5.0 and 6.8 to a solution of growth hormone or derivatives. (b) growing growth hormone crystals at a temperature from about 0 to 30° C. and (c) isolating the cation crystals.

Abstract: Disclosed is a method of preparing zinc free rapid acting insulin analogue. In one embodiment insulin crystals are prepared by providing a solution of an analogue having a pH between 7 and 9.5. The solution is mixed with a salt of an alkali metal or salt and formed crystals are recovered.

Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 Å.

Abstract: Described is an electronic injection device wherein an electronic circuit is designed to work in two alternative modes: an air shot mode and a dose injection mode. When working in the air shot mode a small predetermined air shot dose is pressed out from the ampule when the injection button is actuated. When working in the injection mode, a dose set by operation of the dose setting means is injected by operation of the injection button. The electronic injection device is normally working in the air shot mode but shifts to work in the dose injection mode when it receives a signal indicating that the dose setting means has been operated. The circuit returns to its air shot mode when receiving a signal indicating that the set dose has been injected. This signal can originate either from a switch indicating that the protection cap is mounted or from a switch indicating that the injection button has been pressed.

Abstract: An injection device made up from a housing, a dose setting and injection mechanism, a dose setting member and an injection button is described. The dose setting and injection mechanism is made as a preassembled unit insertable into the housing. Both the dose setting member and the injection button is thereafter connected to the preassembled dose setting and injection mechanism inside the boundaries of the housing, while being accessible for a user from outside the housing. The same preassembled dose setting and injection mechanism can fit into a large variety of different houses making production of different variants of an injection device somewhat easier.

Abstract: The present invention relates to a method and a system for producing an elongated drug formulation being suitable for being injected through the skin of a patient with-out the use of a needle or a cannula. The drug formulation is produced by compressing a drug granulate in cavity of a system comprising a roller and a surface, wherein the roller roles over the surface thereby comprising the granulate to the formulation.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: A method for clinical surveillance of a treatment group and an other group involves defining an adverse event, possible a serious adverse event, noting each occurrence of the adverse events, and, starting at zero, calculating a cumulative sum of the adverse events by updating the cumulative sum each time a further adverse event is reported and, when the adverse event is in the treatment group, adding 1 to the cumulative sum, and, when the adverse event is in the other group, adding 0 to the cumulative sum. This invention also involves subtracting a chosen quantity K from the cumulative sum, comparing the cumulative sum to a predetermined alarm limit, determining when the cumulative sum reaches at least the predetermined alarm limit, and indicating the predetermined alarm limit has been reached.

Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Abstract: A disposable lancet combined with a reagent carrying strip which carries a reagent that indicates the concentration of a blood component in a blood sample placed in contact with the strip. The reagent carrying strip is connected to the lancet, e.g. by molding. One end of the lancet is sharpened for piercing the skin. The strip is sheet-like and has a first side and a second side, which sides are both accessible for the user, such that the reagent carrying strip can be inserted into a blood glucose meter. A weakened tear line is provided at a connection between the lancet and an edge of the reagent carrying strip so that the reagent carrying strip may be easily disconnected from the lancet.

Abstract: The present invention relates to a method for extractive refolding of scrambled and/or polymerised single-chain polypeptides or proteins into their native conformation directly from a microbial fermentation broth.

Abstract: The invention relates to the use of glycylglycine, optionally in combination with a sugar, and/or a sugar alcohol, and/or an amino acid, as a bulking agent in freeze-drying.

Abstract: A drug delivery device comprising a housing (1) with a drug container (2) being provided with delivering means comprising a piston (5) for expelling a drug (4) from the drug container (2). The housing (1) further comprising a displaceable piston rod (6) abutting the piston (5) of the drug container (2) and rotating means being in engagement with the piston rod (6), said rotating means being provided with a one-way mechanism. The one-way mechanism comprises a helical spring (12) wound tightly around an axle (11), one end of said helical spring (12) being fixed in relation to the housing (1), the other end of the helical spring (12) being in a free state.

Abstract: In vitro fertilization can be improved by adding a meiosis activating compound.

Abstract: The present invention relates to a medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly. The cartridge assembly comprises a cartridge having a stopper adapted to receive a plunger. Furthermore, the cartridge assembly has one end sealed with a pierce able sealing, said end comprising coupling device for engaging a needle assembly, and another end comprising coupling device for engaging the dosing assembly. The dosing assembly comprises a plunger and has coupling device for engaging the cartridge assembly. The cartridge assembly and the dosing assembly are coupled together for delivering selected doses of medication. The device further comprises mechanism for securing that the plunger abuts on the stopper during use of the device, in particular when the dosing assembly is releasable coupled to the cartridge assembly.

Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.

Abstract: By a cylinder ampoule (1), comprising a tubular vessel with a membrane (4) sealingly closing one end and a piston (9) closing the other end, liquid stored between said piston (9) and said membrane (4) can be pressed out through an injection needle (7) piercing the membrane (4) when the piston (9) is pressed into the ampoule (1). The tube is made from a plastically deformable material. A pressure foot (10) on which a piston rod (13) is acting abuts the piston (9), carries a spring plate (11) made from a harder material than is the ampoule (1), is mainly perpendicular to the ampoule (1) axis, and has at least one diameter which is larger than the inner diameter of the ampoule (1) so that edges of the plate (11) abutting the inner wall of the ampoule (1) are deflected away from the piston (9) to form an acute angle with said wall.

Abstract: A readily-soluble freeze-dried solid preparation of hGH with a minimal content of degradation products in terms of deamidation, dimers, polymers, and sulphoxide forms, obtainable by a method comprising a single lyophilization of an aqueous slurry of an amorphous hGH isoprecipitate, the slurry having a pH of from about 4.7 to 5.0 and being essentially free of buffer components other than acetate.